26
|
Abdel Azim S, Peer M, Reimer D, Fiegl H, Marth C, Zeimet AG. Einfluss der L1CAM Expression am Ovarialkarzinom auf die Krankheitsprogression und das Überleben. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1548601] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
27
|
Wagener A, Zeimet AG, Reimer D, Hefler L, Koch H. Wertigkeit der Omentektomie bei serös papillärem und klarzelligem Endometriumkarzinom. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1548625] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
28
|
Schmid G, Reimer D, Fiegl H, Marth C, Zeimet AG. Die Rolle der Expression von miR-34a und dessen Promotor-Methylationsstatus beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2015. [DOI: 10.1055/s-0035-1548620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
29
|
Reitsamer R, Zeimet AG. Vorwort. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336815] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
30
|
Abdel Azim S, Reimer D, Maier H, Müller-Holzner E, Oberwalder M, Zeimet AG, Marth C. Ein seltener Uterustumor wird zum PECom der Darmwand - ein Fallbericht. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
31
|
Peer M, Fellner W, Seeber BE, Zeimet AG, Marth C. Primäres Endometriumkarzinom am Mons pubis - Ein Case Report. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1336814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
32
|
Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, Hatina J. Ovarian cancer stem cells. Neoplasma 2013; 59:747-55. [PMID: 22862176 DOI: 10.4149/neo_2012_094] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Because of its semi-solid character in dissemination and growth, advanced ovarian cancer with its hundreds of peritoneal tumor nodules and plaques appears to be an excellent in vivo model for studying the cancer stem cell hypothesis. The most important obstacle, however, is to adequately define and isolate these tumor-initiating cells endowed with the properties of anoikis-resistance and unlimited self-renewal. Until now, no universal single marker or marker constellation has been found to faithfully isolate (ovarian) cancer stem cells. As these multipotent cells are known to possess highly elaborated efflux systems for cytotoxic agents, these pump systems have been exploited to outline putative stem cells as a side-population (SP) via dye exclusion analysis. Furthermore, the cells in question have been isolated via flow cytometry on the basis of cell surface markers thought to be characteristic for stem cells.In the Vienna variant of the ovarian cancer cell line A2780 a proof-of-principle model with both a stable SP and a stable ALDH1A1+ cell population was established. Double staining clearly revealed that both cell fractions were not identical. Of note, A2780V cells were negative for expression of surface markers CD44 and CD117 (c-kit). When cultured on monolayers of healthy human mesothelial cells, green-fluorescence-protein (GFP)-transfected SP of A2780V exhibited spheroid-formation, whereas non-side-population (NSP) developed a spare monolayer growing over the healthy mesothelium. Furthermore, A2780V SP was found to be partially resistant to platinum. However, this resistance could not be explained by over-expression of the "excision repair cross-complementation group 1" (ERCC1) gene, which is essentially involved in the repair of platinated DNA damage. ERCC1 was, nonetheless, over-expressed in A2780V cells grown as spheres under stem cell-selective conditions as compared to adherent monolayers cultured under differentiating conditions. The same was true for the primary ovarian cancer cells B-57.In summary our investigations indicate that even in multi-passaged cancer cell lines hierarchic government of growth and differentiation is conserved and that the key cancer stem cell population may be composed of small overlapping cell fractions defined by various arbitrary markers.
Collapse
|
33
|
Boesch M, Reimer D, Sopper S, Wolf D, Zeimet AG. Crossroads of Drug Resistance and Stem-Like Properties in Ovarian Cancer. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
34
|
Huemer D, Reimer D, Fessler S, Zeimet AG, Marth C. Peri- und postoperative Komplikationen der Debulking-Operation beim Ovarial-Carcinom an der Universitätsklinik für Frauenheilkunde Innsbruck von 2006-2011. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309224] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
35
|
Grimm C, Hofstetter G, Concin N, Marth C, Zeimet AG, Heinze G, Natter C, Rahhal-Schupp J, Reinthaller A, Polterauer S. Die Vorhersage des Gesamtüberlebens von Frauen mit Zervixkarzinom anhand eines Nomogramms. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309233] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
36
|
Jerabek-Klestil S, Widschwendter A, Abdel-Azim S, Müller-Holzner E, Fessler S, Georgoulopoulos A, Zelger B, Maier H, Fiegl M, Marth C, Zeimet AG. Immunhistochemische Charakterisierung neuroendokrin differenzierter kleinzelliger Zervixkarzinome. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
37
|
Hatina J, Reimer D, Sopper S, Boesch M, Martowicz A, Rössler J, Wiedemair A, Wolf D, Zeimet AG. Tumorstammzellen und die Biologie der Chemoresistenz beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
38
|
Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Rahhal-Schupp J, Zeimet AG, Marth C, Reinthaller A, Concin N, Polterauer S. Der prognostische Wert von Gamma-Glutamyltransferase (GGT) in Patientinnen mit Ovarialkarzinom. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
39
|
Reitsamer R, Zeimet AG. EDITORIAL. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309193] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
40
|
Wasle IKC, Boesch M, Sopper S, Reimer D, Wolf D, Zeimet AG. Identification of Cancer Stem Cells in Primary Ovarian Carcinoma. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
41
|
Hubalek M, Bartsch R, Gnant M, Kapp KS, Lang A, Lax S, Lukas P, Neunteufel W, Pristauz G, Reitsamer R, Sandbichler P, Schrenk P, Singer C, Tamussino K, Tschmelitsch J, Zeimet AG, Marth C. Axillary Dissection in the Case of Positive Sentinel Lymph Nodes: Results of the Innsbruck Consensus Conference. Geburtshilfe Frauenheilkd 2012; 72:293-298. [PMID: 25284834 DOI: 10.1055/s-0031-1298441] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
The prognosis of breast cancer is most heavily influenced by the status of the axillary nodes. Until a few years ago, this knowledge was gained through radical axillary lymph node clearance. In the meantime, sentinel lymph node clearance has become an established part of the surgical treatment of breast cancer. With the development of this procedure, the morbidity caused by axillary dissection has been reduced significantly. Although comprehensive prospective, randomised data regarding the safe use of the sentinel concept are only now available, the focus currently, however, is on the question of whether in the case of positive sentinel lymph nodes, an axillary dissection can be done away with altogether without having any negative impact on the risk of loco-regional recurrence or on progression-free survival and overall survival. The results of the American ACOSOG-Z001 study have changed the fundamental perspective of this. In this study on the advantages of axillary dissection following the confirmation of tumour tissue in the sentinel lymph nodes, there were no statistically significant advantages from axillary dissection for women with a favourable overall risk profile who had received radiotherapy and systemic therapy. If this concept takes hold, the surgical treatment of node-positive breast cancer, at least in the axilla, would be reduced to a minimum, and the focus of treatment would in future lie more on the systemic treatment of this condition. As part of an interdisciplinary consensus meeting, a standardised approach for Austria with regard to this question was decided upon.
Collapse
|
42
|
Abdel-Azim S, Reimer D, Müller-Holzner E, Marth C, Zeimet AG. Immunhistochemischer Nachweis von L1-CAM im Stromasarkom und Carcinosarkom (MMMT) des Uterus. Geburtshilfe Frauenheilkd 2012. [DOI: 10.1055/s-0032-1309194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
43
|
Bondong S, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I, Braicu I, Sehouli J, Mahner S, Fogel M, Altevogt P. Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NF-κB activation. Ann Oncol 2012; 23:1795-802. [PMID: 22228447 DOI: 10.1093/annonc/mdr568] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Overexpression of L1-cell adhesion molecule (L1CAM) has been observed for various carcinomas and correlates with poor prognosis and late-stage disease. In vitro, L1CAM enhances proliferation, cell migration, adhesion and chemoresistance. We tested L1CAM and interleukin-1 beta (IL-1β) expression in tumor samples and ascitic fluid from ovarian carcinoma patients to examine its role as a prognostic marker. PATIENTS AND METHODS We investigated tumor samples and ascitic fluid from 232 serous ovarian carcinoma patients for L1CAM by enzyme-linked immunosorbent assay. L1CAM expression was correlated with pathoclinical parameters and patients' outcome. IL-1β levels were measured in tumor cell lysates. Ovarian cancer cell lines were analyzed for the contribution of L1CAM to IL-1β production and nuclear factor 'kappa-light-chain-enhancer' of activated B-cells (NF-κB) activation. RESULTS We observed that L1CAM-expressing tumors show a highly invasive phenotype associated with restricted tumor resectability at primary debulking surgery and increased lymphogenic spread. Soluble L1CAM proved to be a marker for poor progression-free survival and chemoresistance. In ovarian carcinoma cell lines, the specific knock-down of L1CAM reduces IL-1β expression and NF-κB activity. CONCLUSIONS L1CAM expression contributes to the invasive and metastatic phenotype of serous ovarian carcinoma. L1CAM expression and shedding in the tumor microenvironment could contribute to enhanced invasion and tumor progression through increased IL-1β production and NF-κB activation.
Collapse
|
44
|
Reimer D, Kiefel H, Hubalek M, Erdel M, Concin N, Hofstetter G, Mueller-Holzner E, Altevogt P, Marth C, Zeimet AG. Epidermal growth factor-mediated signaling in ovarian cancer and the role of miR-34a and 6p22 gene amplification-based E2F3a control. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15535] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Zeimet AG, Abdel-Azim S, Reimer D, Mueller-Holzner E, Winterhoff B, Puistola U, Ben-Arie A, vanKempen L, Amant F, Petru E, Jahn S, Polterauer S, Oppelt P, Weigert M, Altevogt P, Huszar M, Marth C, Fogel M. Large international multicenter evaluation of the clinical significance of L1-CAM expression in FIGO stage I, type 1 endometrial cancer. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5091] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
46
|
Reimer D, Kiefel H, Erdel M, Müller-Holzner E, Fiegl H, Marth C, Altevogt P, Zeimet AG. 6p22-Genamplifikation und Methylierung des miR-34a Promoters, zwei EGF-R unabhängige Mechanismen der E2F3a-Regulation beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1280643] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
47
|
Hofstetter G, Berger A, Schuster E, Wolf A, Holzer B, Fiegl H, Marth C, Zeimet AG, Tong D, Zeillinger R, Concin N. Die N-terminal verkürzten p53-Isoformen Δ40p53 und Δ133p53 beeinflussen die Prognose bei Patientinnen mit fortgeschrittenen serösen Ovarialkarzinomen - eine prospektive Multizenterstudie. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1280632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
48
|
Hofstetter G, Berger A, Schuster E, Chamson M, Müller-Holzner E, Marth C, Zeimet AG, Zeillinger R, Concin N. Die klinische Bedeutung des MDM2 SNP 309 beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1280631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022] Open
|
49
|
Wolf DG, Fong D, Scherrer L, Wolf A, Reimer D, Marth C, Mueller-Holzner E, Braun S, Zeimet AG. Treg and T eff in the bone marrow of early-stage breast cancer patients with disseminated tumor cells. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e21049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
50
|
Braicu EI, Zeillinger R, Vergote IB, Mahner S, Zeimet AG, Cadron I, Castillo-Tong D, Chekerov R, Brandt B, Sehouli J. Use of HE4 expression in plasma to predict operative outcome in patients with ovarian cancer (OC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5022] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|